Literature DB >> 11179039

ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat.

B K Podesser1, D A Siwik, F R Eberli, F Sam, S Ngoy, J Lambert, K Ngo, C S Apstein, W S Colucci.   

Abstract

Endothelin (ET) A (ET(A)) receptors activate matrix metalloproteinases (MMP). Since endothelin-1 (ET) is increased in myocardium late postmyocardial infarction (MI), we hypothesized that stimulation of ET(A) receptors contributes to activation of myocardial MMPs late post-MI. Three days post-MI, rats were randomized to treatment with the ET(A)-selective receptor antagonist sitaxsentan (n = 12) or a control group (n = 12). Six weeks later, there were rightward shifts of the left ventricular (LV) end-diastolic and end-systolic pressure-volume relationships, as measured ex vivo by the isovolumic Langendorff technique. Both shifts were markedly attenuated by sitaxsentan. In LV myocardium remote from the infarct, the activities of MMP-1, MMP-2, and MMP-9 were increased in the post-MI group, and the increases were prevented by sitaxsentan treatment. Expression of tissue inhibitor of MMP-1 was decreased post-MI, and the decrease was prevented by sitaxsentan treatment. Chronic post-MI remodeling is associated with activation of MMPs in myocardium remote from the infarct. Inhibition of ET(A) receptors prevents MMP activation and LV dilation, suggesting that ET, acting via the ET(A) receptor, contributes to chronic post-MI remodeling by its effects on MMP activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179039     DOI: 10.1152/ajpheart.2001.280.3.H984

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  16 in total

1.  The role of endothelin in the pathogenesis of heart failure.

Authors:  John R Teerlink
Journal:  Curr Cardiol Rep       Date:  2002-05       Impact factor: 2.931

Review 2.  Matrix metalloproteinases: pathways of induction by bioactive molecules.

Authors:  Toshihiro Tsuruda; Lisa C Costello-Boerrigter; John C Burnett
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

Review 3.  Endothelins: pathophysiology and treatment implications in chronic heart failure.

Authors:  John R Teerlink
Journal:  Curr Heart Fail Rep       Date:  2005-12

Review 4.  Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2008-02-07       Impact factor: 4.214

5.  Endothelial endothelin B receptor-mediated prevention of cerebrovascular remodeling is attenuated in diabetes because of up-regulation of smooth muscle endothelin receptors.

Authors:  Aisha I Kelly-Cobbs; Alex K Harris; Mostafa M Elgebaly; Weiguo Li; Kamakshi Sachidanandam; Vera Portik-Dobos; Maribeth Johnson; Adviye Ergul
Journal:  J Pharmacol Exp Ther       Date:  2010-12-23       Impact factor: 4.030

6.  Differential roles of endothelin-1 in angiotensin II-induced atherosclerosis and aortic aneurysms in apolipoprotein E-null mice.

Authors:  Renée S Suen; Sarah N Rampersad; Duncan J Stewart; David W Courtman
Journal:  Am J Pathol       Date:  2011-06-29       Impact factor: 4.307

7.  Inhibition of matrix metalloproteinase activity prevents increases in myocardial tumor necrosis factor-alpha.

Authors:  David B Murray; Scott P Levick; Gregory L Brower; Joseph S Janicki
Journal:  J Mol Cell Cardiol       Date:  2010-04-18       Impact factor: 5.000

Review 8.  Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates.

Authors:  Rugmani Padmanabhan Iyer; Lisandra E de Castro Brás; Yu-Fang Jin; Merry L Lindsey
Journal:  Circ Res       Date:  2014-02-28       Impact factor: 17.367

9.  ETA selective receptor antagonism prevents ventricular remodeling in volume-overloaded rats.

Authors:  David B Murray; Ronald McMillan; Gregory L Brower; Joseph S Janicki
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

10.  CPU86017 and its isomers improve hypoxic pulmonary hypertension by attenuating increased ETA receptor expression and extracellular matrix accumulation.

Authors:  Na Li; De-Zai Dai; Yin Dai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.